Could a common supplement ease long COVID in teens?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects must be between 10 and 17 years of age at the time of study enrollment 2. Positive COVID-19 test by nasopharyngeal swab RT-PCR test, antibody or antigen tests at least 3 months prior to trial; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019, and at least 3 months prior to trial enrollment. 3. If participants have treatable symptoms, they should have had a stable regimen of treatment prior to entering the study (i.e. started treatment for at least 4 weeks). 4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive testing or the date of first symptoms. 5. Lingering symptoms from COVID-19 present at the time of trial enrollment. 6. Individuals of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use at least one highly effective method of contraception while on study treatment. Highly effective methods of contraception must be discussed and approved by the overseeing Investigator. 7. Medication(s) only available through a prescription for the purposes of treating fatigue or cognitive function have been discontinued for four weeks prior to randomization. 8. Participants must be able to assent to their participation in the study and be both willing and able to comply with study requirements. 9. Parents/caregivers/guardians must be able to provide informed consent for participation. 10. Participants must agree to avoid taking supplemental taurine (e.g. from over-the-counter preparations, energy drinks, etc.) Exclusion Criteria: 1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19. 2. Current end-organ failure, organ transplantation, or current hospitalization in an acute care hospital. 3. Contraindications to the study intervention. 4. Currently already on the study intervention (Participants would be eligible if they stopped taking Taurine for a minimum of 4 weeks prior to enrollment). 5. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted). 6. Currently pregnant or breastfeeding. 7. The participant is currently enrolled in another research trial to treat neurocognitive symptoms in LC.